GB201115937D0 - 18F-labelled compounds for use as positron emission imaging agents - Google Patents
18F-labelled compounds for use as positron emission imaging agentsInfo
- Publication number
- GB201115937D0 GB201115937D0 GB201115937A GB201115937A GB201115937D0 GB 201115937 D0 GB201115937 D0 GB 201115937D0 GB 201115937 A GB201115937 A GB 201115937A GB 201115937 A GB201115937 A GB 201115937A GB 201115937 D0 GB201115937 D0 GB 201115937D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- positron emission
- imaging
- compounds
- disease
- imaging agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000012216 imaging agent Substances 0.000 title abstract 3
- 238000003384 imaging method Methods 0.000 abstract 3
- -1 18F-fluorinated barbiturate compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 229910052751 metal Inorganic materials 0.000 abstract 2
- 239000002184 metal Substances 0.000 abstract 2
- 150000002739 metals Chemical class 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 238000002600 positron emission tomography Methods 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000027484 GABAA receptors Human genes 0.000 abstract 1
- 108091008681 GABAA receptors Proteins 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical class O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 238000013456 study Methods 0.000 abstract 1
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates generally to the field of diagnostic methods. More specifically, the present invention pertains to certain 18F-labelled barbiturate compounds of the following formula (collectively referred to herein as "18F-fluorinated barbiturate compounds" and "18FBAR compounds") that bind to metals, for example, metals associated with protein aggregates, and as such are useful as imaging agents for positron emission imaging (e.g., positron emission tomography (PET) imaging) used in the diagnosis and monitoring of conditions involving these aggregates, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). These compounds also bind strongly to GABAA receptors and hence are also useful as imaging agents for positron emission tomography (PET) imaging used in the diagnosis, monitoring and study of diseases involving dis-regulation of these receptors, including epilepsy, schizophrenia, and mood disorders (e.g., anxiety).
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201115937A GB201115937D0 (en) | 2011-09-14 | 2011-09-14 | 18F-labelled compounds for use as positron emission imaging agents |
| PCT/GB2012/052206 WO2013038153A1 (en) | 2011-09-14 | 2012-09-07 | 18f-labelled barbiturate compounds for use as positron emission imaging agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201115937A GB201115937D0 (en) | 2011-09-14 | 2011-09-14 | 18F-labelled compounds for use as positron emission imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201115937D0 true GB201115937D0 (en) | 2011-10-26 |
Family
ID=44908608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB201115937A Ceased GB201115937D0 (en) | 2011-09-14 | 2011-09-14 | 18F-labelled compounds for use as positron emission imaging agents |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201115937D0 (en) |
| WO (1) | WO2013038153A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11518754B2 (en) | 2017-02-17 | 2022-12-06 | Yale University | Radiolabeled pharmaceuticals and methods of making and using same |
| CN113201007A (en) * | 2021-05-31 | 2021-08-03 | 四川大学华西医院 | Fluorescent probe for detecting fluorine ions, application thereof and method for detecting fluorine ions in sample to be detected |
| CN114479101B (en) * | 2022-01-22 | 2023-01-17 | 中北大学 | A supramolecular gel composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1989A (en) | 1841-02-20 | Stump-extractor | ||
| GB1073299A (en) | 1964-08-21 | 1967-06-21 | Aspro Nicholas Ltd | Improvements in or relating to the manufacture of barbituric acid derivatives |
| US4833148A (en) | 1987-04-09 | 1989-05-23 | Washington University | Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury |
| EP1089654A4 (en) | 1998-06-26 | 2004-06-23 | Medical Indicators Inc | Liquid crystal thermometer |
| CA2335459A1 (en) | 1998-06-26 | 2000-01-06 | Card Tech, Inc. | Data system with support surfaces for reciprocating data head |
| CA2471436C (en) | 2002-01-30 | 2011-10-11 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbituric acid derivatives |
| NI200300045A (en) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | INHIBITORS OF TRIARILOXIARILOXIPIRIMIDIN-2,4,6-METALOPROTEINASE TRION. |
| GB0223249D0 (en) | 2002-10-08 | 2002-11-13 | Amersham Plc | Improved imaging agents |
-
2011
- 2011-09-14 GB GB201115937A patent/GB201115937D0/en not_active Ceased
-
2012
- 2012-09-07 WO PCT/GB2012/052206 patent/WO2013038153A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013038153A1 (en) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX356800B (en) | Humanized tau antibody. | |
| WO2013067451A3 (en) | Methods and compositions for diagnosing, prognosing, and treating neurological conditions | |
| JO3702B1 (en) | New gadolinium chelate compounds for use in magnetic resonance imaging | |
| MX375282B (en) | PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILLAR TANGLES. | |
| MX2013012526A (en) | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders. | |
| MY164579A (en) | Safe and functional humanized antibodies | |
| EP2895621A4 (en) | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF NEUROLOGICAL CONDITIONS | |
| WO2014160871A3 (en) | Methods and agents for treating alzheimer's disease | |
| PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| EP2795325A4 (en) | DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE | |
| BR112014012822A2 (en) | fluorine-18 and carbon-11 labeled radioligents for positron emission tomography (pet) imaging for lrrk2 | |
| BR112014000637A2 (en) | diagnosis of alzheimer's disease | |
| EP2331955A4 (en) | DIAGNOSTIC METHOD FOR RESPIRATORY DISEASE | |
| PL2764367T3 (en) | Method for diagnosing alzheimer's disease (ad) | |
| EP2893343A4 (en) | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF INFLAMMATORY HEPATIC DISEASE | |
| Waerzeggers et al. | Mouse models in neurological disorders: applications of non-invasive imaging | |
| EA201691831A1 (en) | HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION AS DOPAMINE D1 LIGANDS | |
| WO2012116196A3 (en) | Substituted lactosyl compounds and use thereof for cellular imaging and therapy | |
| CO2020008834A2 (en) | New method to prepare compound for imaging | |
| MY196981A (en) | Compounds for imaging tau protein aggregates | |
| ECSP11010850A (en) | NEW SUITABLE COMPOUNDS AS COMPOUND PRECURSORS THAT ARE USEFUL TO OBTAIN IMAGES OF AMYLOOID DEPOSITS | |
| GB201115937D0 (en) | 18F-labelled compounds for use as positron emission imaging agents | |
| EA201300479A1 (en) | CONNECTIONS FOR APPLICATION IN VISUALIZATION, DIAGNOSTICS AND / OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| EP2791676A4 (en) | DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE | |
| EP2667896A4 (en) | METHODS AND COMPOSITIONS SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |